AgingPhase 2NCT07104929
Beta Glucan 500 and Biological Age and Immune Age
A Phase 2 study testing Beta Glucan in people with Aging, run by OvationLab at 1 site in United States.
Trial summary
The primary purpose of this study is to evaluate the effects of BWH Labs - Beta Glucan 500 on biomarkers of biological and immune age among healthy adults. A single-arm, open-label prospective study will be conducted evaluating the impact of 12 weeks of supplementation with two capsules daily of Beta Glucan 500 on a… Read more about this study
- Who is it for?
- Ages 40 years and olderHealthy volunteers can take part
- Conditions the study is for
- Aging
- What is being tested?
- Beta Glucan
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteUnited States
- Study dates
- 14 May 2025to 9 Oct 2025
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adult females or males age ≥ 40 years
- Ability to read and speak English
- Previous completion of a TruDiagnostic TruAge test within the past three months to enable comparison of previous biomarkers to the same biomarkers after intervention
- DunedinPACE estimate of aging >0.9
Who cannot join
- Current diagnosis and treatment for an autoimmune condition
- Current use of beta-glucan or mushroom dietary supplement
- Known allergies to beta glucan, yeast, or mushrooms
- Currently pregnant or lactating women or women planning to become pregnant in the next 12 weeks
- Current diagnosis of a chronic health condition (e.g., cancer, heart failure, history of pancreatitis, type I or II diabetics on insulin) deemed clinically contraindicated for the study protocol
- Participants unable to provide consent
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Prospective Human Study Evaluating the Effects of Beta Glucan 500 on Markers of Biological Age and Immune Age: An Open-label Pilot Study
The primary purpose of this study is to evaluate the effects of BWH Labs - Beta Glucan 500 on biomarkers of biological and immune age among healthy adults.
A single-arm, open-label prospective study will be conducted evaluating the impact of 12 weeks of supplementation with two capsules daily of Beta Glucan 500 on a variety of validated markers of biological and immune age on the comprehensive TruAge panel (TruDiagnostics, Lexington, KY).
- Conditions
- Aging
- Being tested
- Beta Glucan
- Keywords
- aging, biological age, immunosenescence, beta glucan
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Beta GlucanDietary supplement
12 weeks of supplementation with two capsules daily of BWH Labs Beta Glucan 500
| Study group | Role | What they receive |
|---|---|---|
| Beta Glucan | Experimental | Not described Receives: Dietary Supplement: Beta Glucan |
What is being measured
The primary outcome is the main question the study is designed to answer.
Epigenetic Testing
Measured: Change from baseline to 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Aug 2025
- Study start14 May 2025
- Primary completion9 Oct 2025
- Study completion9 Oct 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AgingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- OvationLab
- Sponsor type
- Research network
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07104929
- Sponsor's protocol ID
- BWH-002
- Status last verified
- Feb 2026
- First submitted
- 28 Jul 2025
- Last updated
- 19 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Private genetic and epigenetic data
Study at a glance
From the registry record, last updated by the sponsor on 19 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Human Study Evaluating the Effects of Beta Glucan 500 on Markers of Biological Age and Immune Age: An Open-label Pilot Study
- ClinicalTrials.gov ID
- NCT07104929
- Acronym / sponsor ID
- BWH-002
- Conditions
- Aging
- Keywords
- aging, biological age, immunosenescence, beta glucan
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- OvationLabResearch network
- Study start
- 14 May 2025 (actual)
- Primary completion
- 9 Oct 2025 (actual)
- Study completion
- 9 Oct 2025 (actual)
- First posted
- 5 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary purpose of this study is to evaluate the effects of BWH Labs - Beta Glucan 500 on biomarkers of biological and immune age among healthy adults.
A single-arm, open-label prospective study will be conducted evaluating the impact of 12 weeks of supplementation with two capsules daily of Beta Glucan 500 on a variety of validated markers of biological and immune age on the comprehensive TruAge panel (TruDiagnostics, Lexington, KY).
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Beta Glucan | Experimental | Dietary Supplement: Beta Glucan |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Adult females or males age ≥ 40 years
- Ability to read and speak English
- Previous completion of a TruDiagnostic TruAge test within the past three months to enable comparison of previous biomarkers to the same biomarkers after intervention
- DunedinPACE estimate of aging >0.9
Key exclusion criteria (6 listed)
- Current diagnosis and treatment for an autoimmune condition
- Current use of beta-glucan or mushroom dietary supplement
- Known allergies to beta glucan, yeast, or mushrooms
- Currently pregnant or lactating women or women planning to become pregnant in the next 12 weeks
- Current diagnosis of a chronic health condition (e.g., cancer, heart failure, history of pancreatitis, type I or II diabetics on insulin) deemed clinically contraindicated for the study protocol
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Beta Glucan12 weeks of supplementation with two capsules daily of BWH Labs Beta Glucan 500 | Dietary supplement | Beta Glucan |
Primary outcome
Epigenetic Testing
Time frame: Change from baseline to 12 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Feb 2026.
- Individual participant dataSharing planned: No. Private genetic and epigenetic data
Related trials for Aging
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
RecruitingPhase 2
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
Multiple Sclerosis
Not yet recruitingPhase 2
Validation & Intervention Testing for Aging, Longevity and Healthspan
Aging, Functional Decline
RecruitingObservational study
Effects of Obesity on Physical Abilities and Daily Living Activities in Elderly Adults
Obesity, Sarcopenic Obesity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Beta Glucan in people with Aging, run by OvationLab at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Epigenetic Testing (time frame: Change from baseline to 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Feb 2026.